

K072332

# 510(k) Summary (As required by 21 CFR 807.92(c))

JAN: 10 2008

510(k) Number:\_\_\_\_\_

**Date Prepared** 

October 1, 2007

**Submitter Information** 

Submitter's Name:

Address:

Vascular Solutions, Inc.

6464 Sycamore Court Minneapolis, MN 55369

Contact Person:

Deborah L. Neymark

Vice President, Regulatory Affairs

Phone 763-656-4349 Fax 763-656-4250

**Device Information** 

Trade Name:

Vari-Lase® WireFiber

Common Name:

Optical Fiber

Class:

TT

Classification Name:

Laser Surgical Instrument for use in General and Plastic

Surgery and in Dermatology

(21 CFR 870.4810, Product Code GEX)

#### **Predicate Device**

Vari-Lase Endovenous Bright<sup>™</sup> Tip Fiber (K070216) manufactured by Vascular Solutions, Inc.

### **Device Description**

The Vari-Lase Wire Fiber is a  $600\mu$ m core laser fiber that is 3.5 meters in length. The distal tip of the fiber is encased in a ceramic and platinum/iridium (provides ultrasound visibility during clinical use) and includes a distal floppy spring tip.

#### Intended Use/Indications for Use

The VARI-LASE WireFiber is indicated for the treatment of varicose veins and varicosities associated with superficial reflux in the Great Saphenous Vein and for treatment of incompetence and reflux of superficial veins in the lower extremity.

### Summary of Testing

Bench testing was conducted on the modified laser fiber and included an assessment of physical properties and its ability to achieve its intended use. The results of the tests confirmed the suitability of the device for its intended use. Bench tests included energy transmission, integrity of the tip following simulated clinical use (tensile strength of the ceramic/metal tip, burn-back, torque response and torsional strength) and biocompatibility.

### Statement of Equivalence

The Vari-Lase Wire fiber is substantially equivalent to the currently marketed Vari-Lase Bright Tip Fiber, based on comparisons of the device classification, indications for use, technological characteristics, and sterilization methods.

#### Conclusion

The Vari-Lase Wire Fiber is substantially equivalent to the currently marketed Vari-Lase Fibers, based on comparisons of the device classifications, indications for use, technological characteristics, and sterilization methods. Bench tests confirmed the suitability of the device for its intended use.





JAN 10 2008

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Vascular Solutions, Inc. % Ms. Deborah Neymark VP, Regulatory Affairs, Clinical Research and Reimbursement 6464 Sycamore Court Minnesapolis, Minnesota 55369

Re: K072332

Trade/Device Name: Vari-Lase® Wire Fiber Regulation Number: 21 CFR 878.4810

Regulation Name: Laser surgical instrument for use in general and plastic surgery and in

dermatology

Regulatory Class: II Product Code: GEX

Dated: November 30, 2007 Received: December 3, 2007

### Dear Ms. Neymark:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

## Page 2 – Ms. Deborah Neymark

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely yours,

Mark N. Melkerson

Mark M Milkern

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

# Indications for Use Statement

510(k) Number: <u>K072332</u>

Device Name:
Vari-Lase® Wire Fiber
Indications for Use:
The VARI-LASE Wire Fiber is indicated for the treatment of varicose veins and varicosities associated with superficial reflux in the Great Saphenous Vein and for treatment of incompetence and reflux of superficial veins in the lower extremity.
Prescription Use X Over-The-Counter Use (Part 21 CFR 801 Subpart D) AND/OR (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Off (Disiple Signal (ODE)
Division of General, Restorative,
and Neurological Devices
510(k) Number 1672332